1. currently treated with an acei, arb or aldosterone antagonist, aliskiren, or arni 2. intolerance of arbs 3. serum potassium \>5.5 mmol/l 4. an estimated glomerular filtration rate (egfr) \<30ml/min/1.732m 5. known biliary obstruction, known severe hepatic impairment (child-pugh-turcotte score 10-15) 6. pregnancy, lactation, or inadequate contraception. 7. participation in a study of a novel investigational product within 28 days prior to randomisation. 8. plans to participate in another study of a novel investigational product during this study.

1. currently treated with an acei, arb or aldosterone antagonist, aliskiren, or arni 2. intolerance of arbs 3. serum potassium \>5.5 mmol/l 4. an estimated glomerular filtration rate (egfr) \<30ml/min/1.732m 5. known biliary obstruction, known severe hepatic impairment (child-pugh-turcotte score 10-15) 6. pregnancy, lactation, or inadequate contraception. 7. participation in a study of a novel investigational product within 28 days prior to randomisation. 8. plans to participate in another study of a novel investigational product during this study.

currently treated with an acei, arb or aldosterone antagonist, aliskiren, or arni intolerance of arbs serum potassium >5.5 mmol/l an estimated glomerular filtration rate (egfr) <30ml/min/1.732m known biliary obstruction, known severe hepatic impairment (child-pugh-turcotte score 10-15) pregnancy, lactation, or inadequate contraception. participation in a study of a novel investigational product within 28 days prior to randomisation. plans to participate in another study of a novel investigational product during this study.

currently treated with an acei, arb or aldosterone antagonist, aliskiren, or arni intolerance of arbs serum potassium >5.5 mmol/l an estimated glomerular filtration rate (egfr) <30ml/min/1.732m known biliary obstruction, known severe hepatic impairment (child-pugh-turcotte score 10-15) pregnancy, lactation, or inadequate contraception. participation in a study of a novel investigational product within 28 days prior to randomisation. plans to participate in another study of a novel investigational product during this study.